Ramipril Capsule
Product Images NDC 70518-4604

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 70518-4604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Ramipril 2.5mg 70518 4604 00)

This text provides information about Ramipril Capsules manufactured by Rising Pharma, Inc. The medication comes in a 2.5mg dosage and is to be stored at 20-25°C. The package contains 50 capsules per box and the NDC number is 70518-4604-00. The medication is orange in color. It also mentions that it is repackaged by RemedyRepack Inc. located in Indiana, PA. The contact number provided is 724-465-8762.*

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Ramipril capsules manufactured by Rising Pharma, Inc. The usual dosage information is available on the insert. The medication should be kept out of reach of children and stored at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). The NDC number for this product is 70518-4604-01. The capsules are orange in color. The product has been repackaged by RemedyRepack Inc., located in Indiana, PA 15701. Contact number: 724-465-8762.*

FDA Label Image

Figure 1 (Ramipril Fig1)

This data presents the proportions of patients at different levels, with a focus on the medication Ramipril. The values indicate the distribution of patients over time (days of follow-up), possibly suggesting the efficacy or impact of Ramipril treatment on the patient population.*

FDA Label Image

Figure 2 (Ramipril Fig2)

This dataset provides information on a study related to cardiovascular health. It includes data on cardiovascular disease, diabetes, age, sex, hypertension, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The study involved 9297 patients, with specific details on various conditions and incidence rates in the placebo group.*

FDA Label Image

Chemical Structure (Ramipril Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.